To delineate receptor-specific contributions to psilocybin-induced glioma proliferation, we used DMG cell lines with CRISPR-mediated knockout of either 5HT2A or NTRK2 (TrkB), another known psilocybin target(28) and a key driver of glioma proliferation(6). Here, NTRK2 is linked to central nervous system cancer.